Microbicides 2004 Microbicides 200428-31 March 2004, Hilton London MetropoleThe conference42 million men, women and children worldwide were living with HIV by the end of December 2002 (source: UNAIDS), including five million newly-infected during that year alone. Another 45 million people will become infected between 2002 and 2010, unless the current transmission rates can be vastly reduced. Of the 42 million, 29.4 million live in sub-Saharan Africa and 58% of them are women. Not only are women more susceptible to HIV infection, many are powerless to insist on the use of condoms or other methods of protecting themselves. In this context, and with the knowledge that an effective HIV vaccine is unlikely to be available for several years, the need for an effective topical microbicide grows ever more urgent. 2004 should prove to be a landmark year in the field of microbicide development as the first Phase III trials of novel products are due to start – the next step along the road to making a microbicide available to the millions worldwide in desperate need of protection.The aims of the Microbicides 2004 conference are to:Report novel or innovative work in the microbicides fieldProvide updates on recent microbicides research, divided into three tracks: basic science, clinical science, and behavioural science (including public health and the microbicide marketplace)Provide a forum for the discussion of new developments in microbicide research including ethical, clinical, behavioural and methodological issuesPresent opportunities for knowledge-sharing between microbicide researchers, public-health workers and advocacy organisations.There will be an opening ceremony on the evening of Sunday 28 March at which politicians, policy makers and the international media are expected. The conference will run for a full three days, each of which will contain:Scientific overviews and presentations with plenary sessions, invited lecturers and presentations of original researchWorkshops to review issues unique to microbicides such as trial design and outcome measures, and ethical issues in the clinical trials of microbicidesPoster sessions. Focus on LondonFollowing the successful Microbicides conferences in Washington in 2000 and Antwerp in 2002, March 2004 sees the focus move to London.The venue is the Hilton Metropole Hotel, two minutes by taxi from Paddington station and the Heathrow Express, with a journey time from the airport of 15 minutes. The hotel is in walking distance of Hyde Park and London’s main shopping streets, and close to Imperial College. Accommodation will be available at the venue and other hotels in the vicinity.London in March offers a variety of diversions for out-of-conference relaxation, including sight-seeing and shopping; the arts and the theatre; and pubs, clubs and restaurants to suit every taste. Conference staff will be on hand to help delegates plan their spare time.To book your place or find out more information, e-mail info@microbicides2004.org.uk or telephone the Event Office on +44 (0) 20 7720 4411
Oral: invited speaker Oral: Track A Oral: Track B Oral: Track C Poster: Track A Poster: Track B Poster: Track C Abstract only Authors

02343_1 PRECLINICAL EVALUATIONS OF DENDRIMER FORMULATIONS IN THE NONHUMAN PRIMATE MODEL

Patton, Dorothy
Cosgrove Sweeney Y, Holan G*, Mc Carthy T*
University of Washington, Seattle, WA USA and *Starpharma, Melbourne, Australia

In developing dendrimers as pharmaceuticals, Starpharma (Melbourne, Australia) has focused on the prevention of human immunodeficiency virus (HIV) and sexually transmitted infections (STIs) with the development of microbicide candidates. An optimized dendrimer-based microbicide, SPL7013 has emerged as a lead candidate and clinical studies are in progress under an Investigational New Drug application (IND) submitted to the United States Food and Drug Administration (FDA).

Three gel formulations of SPL7013 (1%, 3% and 5% w/w) have been assessed in our nonhuman primate (NHP) model for safety studies with repeated vaginal application. Each product was applied to six animals daily for 4 days. Effects of product use were assessed at baseline and 24-hours after each application by colposcopy, vaginal pH and microbiology measures. Acute shifts in pH and microbiology were also assessed 30-minutes after each product application. Finally, vaginal and cervical biopsies were collected at baseline and 24-hours after the final product application, to determine presence of product-induced inflammatory infiltrate.

The 1% and 3% SPL7013 gel formulations performed similar to placebo gel, for all the parameters assessed and no measures of tissue irritation were noted. Repeated applications of the 5% SPL7013 product did not cause any changes to vaginal flora and no abnormalities were detected in biopsy samples although abnormal colposcopic findings were detected in 4 of 6 animals.

This work supported by NIH contract N01-AI-95388 and U of WA National Primate Research Center RR-00166.

Dr. Dorothy Patton
University of Washington, Box 356460, Ob-Gyn, Seattle, WA 98195-6460 USA
(Telephone) 206-543-5554 (Fax) 206-616-9479 (E-mail) dpatton@u.washington.edu